Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Complete title: ADVL1217, A Phase 1 Study of MK-1775 (IND#116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas

Research Study Number ADVL1217
Principal Investigator Julie Park, MD
Phase I

Research Study Description

This phase I trial studies the side effects and the best dose of WEE1 inhibitor MK-1775 when given together with local radiation therapy in treating patients with newly diagnosed diffuse intrinsic pontine gliomas. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving WEE1 inhibitor MK-1775 with local radiation therapy may work better than local radiation therapy alone in treating diffuse intrinsic pontine gliomas.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ADVL1217
Contact Advanced Therapeutics Study Line
Telephone 206/987-2553

Keywords: Glioma; Pediatric Cancers, Miscellaneous; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Glioblastoma; Astrocytoma; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Gliosarcoma; Oligodendroglioma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials